Biocon Reports ₹1,429 Cr Profit, Recommends 10% Dividend and Ups Biocon Biologics Stake

HEALTHCAREBIOTECH
Whalesbook Corporate News Logo
AuthorAarav Shah|Published at:
Biocon Reports ₹1,429 Cr Profit, Recommends 10% Dividend and Ups Biocon Biologics Stake
Overview

Biocon announced its audited FY26 results, posting a consolidated profit of ₹1,429.40 crore on ₹16,927 crore revenue. The board recommended a 10% final dividend and approved acquiring an additional ~2% stake in its subsidiary, Biocon Biologics (BBL). New auditors, S. R. Batliboi & Associates LLP, were appointed for five years. The standalone profit was affected by one-off charges.

Instant Stock Alerts on WhatsApp

Used by 10,000+ active investors

1

Add Stocks

Select the stocks you want to track in real time.

2

Get Alerts on WhatsApp

Receive instant updates directly to WhatsApp.

  • ✓Quarterly Results
  • ✓Concall Announcements
  • ✓New Orders & Big Deals
  • ✓Capex Announcements
  • ✓Bulk Deals
  • ✦And much more
Add StocksGet it on Google PlayDownload on the App Store

Biocon Reports ₹1,429 Cr Profit for FY26, Recommends 10% Dividend and Buys More Biocon Biologics Stake

Financial Results and Dividend

Biocon Ltd. has announced its audited financial results for the fiscal year ending March 31, 2026. The company posted consolidated revenue of ₹16,927 crore and a consolidated net profit of ₹1,429.40 crore.

The board has recommended a final dividend of 10%, which translates to ₹0.50 per equity share. This dividend payout is subject to shareholder approval, with a record date set for July 3, 2026.

Strategic Moves: BBL Stake and Auditors

In a strategic move, Biocon approved acquiring an additional stake of approximately 2% in its subsidiary, Biocon Biologics Limited (BBL), for up to ₹330.73 crore. This acquisition, to be funded through a preferential issue of Biocon shares, further strengthens Biocon's control over BBL, building on its previous 15% acquisition in 2022.

The company also appointed S. R. Batliboi & Associates LLP as its new statutory auditors for a five-year term, replacing B S R & Co. LLP. Additionally, several director appointments were approved, which will require shareholder consent.

Standalone Profit Context and Market Landscape

Biocon's standalone net profit for FY26 saw a significant decline, mainly due to exceptional items. These one-off charges include impacts from labor code changes, share swap agreements, and legal settlements.

Biocon operates in the competitive biosimilars and biopharmaceuticals market, facing rivals such as Dr. Reddy's Laboratories, Sun Pharmaceutical Industries, and Cipla. These companies are also investing heavily in research and development and expanding product pipelines.

Outlook

The recommended dividend offers a direct return to shareholders, while the increased stake in Biocon Biologics reinforces the company's focus on its key subsidiary. The transition to a new audit firm, S. R. Batliboi & Associates LLP, will oversee financial reporting for the next five years, and new board members are expected to bring diverse perspectives.

Get stock alerts instantly on WhatsApp

Quarterly results, bulk deals, concall updates and major announcements delivered in real time.

Add Stocks
Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.